PT-2977

Unassigned

New Medicines

Von Hippel Lindau Disease-associated renal cell carcinoma

Information

New molecular entity
Peloton Therapeutics
Peloton Therapeutics

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Potent, selective HIF-2α inhibitor. Selective inhibition of HIF-2α transcription factor leads to impaired hypoxic signalling in cancer cells and blocks transcription of several genes involved in oncogenesis [1,2]
The incidence of VHL disease is about 1 per 36,000 live births. Approx 60% of all patients with VHL will develop RCC or renal cysts. Both are typically bilateral and found in multiple locations within the kidney. RCCs are found in 24% to 45% of patients with VHL and are the primary inherited renal cancer. The mean age of RCC onset is 39 years old, which is 25 years less than the mean age of the typical patient [3].
Von Hippel Lindau Disease-associated renal cell carcinoma
Oral

Renal cell carcinoma; advanced, clear-cell - second-line

Information

New molecular entity
Peloton Therapeutics
Peloton Therapeutics

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Potent, selective HIF-2α inhibitor. Selective inhibition of HIF-2α transcription factor leads to impaired hypoxic signalling in cancer cells and blocks transcription of several genes involved in oncogenesis [1,2]
RCC affects ~4 in 10,000 people in the EU, equivalent to a total of ~203,000 people
Renal cell carcinoma; advanced, clear-cell - second-line
Oral